Patents Examined by Sarah Pihonak
  • Patent number: 10660962
    Abstract: The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: May 26, 2020
    Assignee: CMPD Licensing, LLC
    Inventors: Jay Richard Ray, II, Charles D. Hodge
  • Patent number: 10653653
    Abstract: The present disclosure provides new salts of 5-aminolevulinic acid (5-ALA) and new salts of 5-ALA esters, their preparation, formulation and use as photosensitizing agents in photodynamic therapy, diagnosis and cosmetic cares.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: May 19, 2020
    Inventors: Ming Zhao, Li-Ming Zhou
  • Patent number: 10653646
    Abstract: The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: May 19, 2020
    Assignee: Nevakar Inc.
    Inventors: Prem Sagar Akasapu, Kumaresh Soppimath, Reema Ajitkumar Puri, Iouri V. Ilitchev, Milan Patel, Pooja H. Tendulkar
  • Patent number: 10653676
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: May 19, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Alan D. D'Andrea, Gregory D. Cuny, Ross L. Stein, Marcie Glicksman, April Case, Jun Xian, David Wilson, Min Huang
  • Patent number: 10653137
    Abstract: A composition to affect an arthropod is described that may include a fatty alcohol, a surface active agent, and a carrier. The composition may include substantially no oil and interrupts production of adipokinetic hormones (AKH) in the arthropod. The composition is introducible to the arthropod via contact or via a liquid application such as a spray. A method of using the composition is described that may include introducing the composition to an environment, causing the arthropod be introduced to the composition, and affecting production of peptides in the arthropod via the composition that affect energy regulation of the arthropod.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: May 19, 2020
    Inventor: Stephen C. Perry
  • Patent number: 10653662
    Abstract: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: May 19, 2020
    Assignees: Currax Pharmaceuticals LLC, ProCom One, Inc.
    Inventors: Roberta L. Rogowski, Susan E. Dubé, Philip Jochelson, Neil B. Kavey
  • Patent number: 10646456
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 12, 2020
    Assignee: Adamas Pharma, LLC
    Inventors: Gregory T. Went, Timothy J. Fultz, Natalie McClure
  • Patent number: 10648977
    Abstract: The invention described herein provides methods for treating a disease or disorder associated with angiotensin receptor signaling in a patient exhibiting elevated levels of ATIR autoantibodies. The invention also provides methods of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker. Patients with elevated levels of ATIR autoantibodies are identified as candidates that particularly benefit from treatment with an angiotensin receptor blocker.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: May 12, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jeremy D. Walston, Peter M. Abadir, Alka Jain, Neal Fedarko
  • Patent number: 10646508
    Abstract: A method of making a composition or a dietary supplement is provided, the method comprising combining a quantity of a Nitrate with a quantity of an Amino Acid Compound, wherein the combining of the Nitrate with the Amino Acid Compound reduces a side effect or toxicity of the Nitrate. Also provided is a method of safely administering to a subject a Nitrate with a reduced side effect or toxicity, the method comprising: combining a quantity of the Nitrate with a quantity of an Amino Acid Compound in a composition or a dietary supplement, wherein the combining of the Nitrate with the Amino Acid Compound reduces the side effect or toxicity of the Nitrate; and safely administering to the subject the composition or dietary supplement comprising the Nitrate with the reduced side effect or toxicity.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: May 12, 2020
    Assignee: THERMOLIFE INTERNATIONAL, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 10632095
    Abstract: The invention describes a long-acting veterinary composition comprising at least one ketoprofen ester prodrug. The composition also comprises at least one veterinary acceptable triglyceride, and optionally, at least one preservative, and optionally, at least one additional veterinary acceptable excipient. The invention also describes a method of treating an animal for fever, pain, and/or inflammation by administering the long-acting composition comprising at least one ketoprofen ester prodrug to the animal in need thereof.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: April 28, 2020
    Assignee: Zoetis Services LLC
    Inventors: Richard Andrew Ewin, Steven X. Hu, Susan M. Machkovech, Barton H. Manning, Stephen Lee Secreast
  • Patent number: 10633388
    Abstract: Pyrazolopyrimidone derivatives and methods of use thereof are described. Specifically, pharmaceutical uses of pyrazolopyrimidone derivatives represented by the general formula (II) and pharmaceutically acceptable salts thereof are described, wherein the definitions of substituents in the general formula (II) are the same as the definitions in the specification. The pyrazolopyrimidone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: April 28, 2020
    Assignees: Shanghai Hengrui Pharmaceutical Co., ltd., Jiangsu Hangrui Medicine Co., Ltd.
    Inventors: Hejun Lu, Piaoyang Sun, Bin Gui, Qing Dong
  • Patent number: 10632124
    Abstract: The present disclosure teaches methods for treating and preventing a variety of neurodegenerative conditions and symptoms associated therewith, including Alzheimer's disease (AD) and idiopathic Parkinson's disease (iPD), by utilizing adrenoceptor antagonists. Adrenoceptor antagonists that can be used include ?-blockers, such as acebutolol, betaxolol, bisopropolol, bopindolol, carvedilol, metoprolol, oxprenolol, propranolol, and timolol. The present disclosure also teaches methods for diagnosing and monitoring the progression of iPD.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: April 28, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Michele Tagliati, Gennaro Pagano
  • Patent number: 10632150
    Abstract: Disclosed herein is a sterile composition for injection comprised of potassium phosphates having no visible particulate. Also disclosed herein is a manufacturing process for the sterile composition and its use.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: April 28, 2020
    Assignee: CMP Development LLC
    Inventors: H. Greg Thomas, Richard LeVasseur, Jeffrey S. Kiel, Anthony Reid Pipho
  • Patent number: 10633374
    Abstract: The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: April 28, 2020
    Assignee: YALE UNIVERSITY
    Inventors: David Spiegel, Anthony Rullo
  • Patent number: 10631539
    Abstract: A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: April 28, 2020
    Assignee: Syngenta Participations AG
    Inventors: Thomas James Hoffman, Sarah Sulzer-Mosse, Kurt Nebel, Fredrik Emil Malcolm Cederbaum, Mathias Blum
  • Patent number: 10624911
    Abstract: Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: April 21, 2020
    Assignee: Helsinn Healthcare SA
    Inventors: Alessio Venturini, Roberta Cannella
  • Patent number: 10617703
    Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 14, 2020
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 10617685
    Abstract: Nonsteroid and steroid compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant, induce apoptosis and inhibit proliferation of inhibiting proliferation and migration of androgen sensitive cancer cells. The steroid compounds and nonsteroid compounds may be agents for the prevention and/or treatment of cancer, including prostate cancer, castration resistant prostate cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, benign prostatic hyperplasia (BPH), Kennedy's disease, androgenetic alopecia, breast cancer, androgen-insensitive syndrome, and spinal and bulbar muscular atrophy.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: April 14, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Vincent C. O. Njar, Puranik Purushottamachar
  • Patent number: 10617694
    Abstract: There is provided for novel therapy of sleep apnea that involves administering the drug sultiame to the patient.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: April 14, 2020
    Inventors: Jan Hedner, Ludger Grote, Kaj Stenlöf
  • Patent number: 10617682
    Abstract: Embodiments relate to compositions comprising a prochlorperazine compound and a nasal carrier, including methods for formulating such compositions for pharmaceutical applications, for example, for treating or reducing the incidence of migraine headaches. Additional embodiments relate to articles comprising a prochlorperazine compound and a nasal carrier, including use of such articles as nasal drops or nasal sprays. Further embodiments relate to methods for using such articles, for example, for treating or reducing the incidence of migraines.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: April 14, 2020
    Assignee: Roseman University of Health Sciences
    Inventor: Venkata Kashyap Yellepeddi